Vineet S Rolston1, Jessica Kimmel1, Violeta Popov1,2, Brian P Bosworth2, David Hudesman2, Lisa B Malter1, Simon Hong1, Shannon Chang3. 1. Division of Gastroenterology, NYU School of Medicine, New York, NY, USA. 2. Division of Gastroenterology, NYU Langone Medical Center, 240 E 38th Street, 23rd Floor, New York, NY, 10016, USA. 3. Division of Gastroenterology, NYU Langone Medical Center, 240 E 38th Street, 23rd Floor, New York, NY, 10016, USA. Shannon.Chang@nyumc.org.
Abstract
GOALS AND BACKGROUND: Ustekinumab (UST) is a monoclonal antibody inhibitor of IL-12/IL-23 approved for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). We conducted a meta-analysis to compare rates of adverse events (AEs) in randomized controlled trials (RCTs) of UST for all indications. STUDY: A systematic search was performed of MEDLINE, Embase, and PubMed databases through November 2019. Study inclusion included RCTs comparing UST to placebo or other biologics in patients aged 18 years or older with a diagnosis of an autoimmune condition. RESULTS: Thirty RCTs with 16,068 patients were included in our analysis. Nine thousand six hundred and twenty-six subjects were included in the UST vs placebo analysis. There was no significant difference in serious or mild/moderate AEs between UST and placebo with an OR of 0.83 (95% CI 0.66, 1.05) and 1.08 (95% CI 0.99, 1.18), respectively, over a median follow-up time of 16 weeks. In a sub-analysis of CD and UC trials, no difference in serious or mild/moderate AEs in UST versus placebo was seen. CONCLUSIONS: UST was not associated with an increase in short-term risk of AEs.
GOALS AND BACKGROUND:Ustekinumab (UST) is a monoclonal antibody inhibitor of IL-12/IL-23 approved for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). We conducted a meta-analysis to compare rates of adverse events (AEs) in randomized controlled trials (RCTs) of UST for all indications. STUDY: A systematic search was performed of MEDLINE, Embase, and PubMed databases through November 2019. Study inclusion included RCTs comparing UST to placebo or other biologics in patients aged 18 years or older with a diagnosis of an autoimmune condition. RESULTS: Thirty RCTs with 16,068 patients were included in our analysis. Nine thousand six hundred and twenty-six subjects were included in the UST vs placebo analysis. There was no significant difference in serious or mild/moderate AEs between UST and placebo with an OR of 0.83 (95% CI 0.66, 1.05) and 1.08 (95% CI 0.99, 1.18), respectively, over a median follow-up time of 16 weeks. In a sub-analysis of CD and UC trials, no difference in serious or mild/moderate AEs in UST versus placebo was seen. CONCLUSIONS:UST was not associated with an increase in short-term risk of AEs.
Authors: Christopher E M Griffiths; Bruce E Strober; Peter van de Kerkhof; Vincent Ho; Roseanne Fidelus-Gort; Newman Yeilding; Cynthia Guzzo; Yichuan Xia; Bei Zhou; Shu Li; Lisa T Dooley; Neil H Goldstein; Alan Menter Journal: N Engl J Med Date: 2010-01-14 Impact factor: 91.245
Authors: Mark Lebwohl; Bruce Strober; Alan Menter; Kenneth Gordon; Jolanta Weglowska; Lluis Puig; Kim Papp; Lynda Spelman; Darryl Toth; Francisco Kerdel; April W Armstrong; Georg Stingl; Alexa B Kimball; Herve Bachelez; Jashin J Wu; Jeffrey Crowley; Richard G Langley; Tomasz Blicharski; Carle Paul; Jean-Philippe Lacour; Stephen Tyring; Leon Kircik; Sergio Chimenti; Kristina Callis Duffin; Jerry Bagel; John Koo; Gary Aras; Joanne Li; Wenjie Song; Cassandra E Milmont; Yifei Shi; Ngozi Erondu; Paul Klekotka; Brian Kotzin; Ajay Nirula Journal: N Engl J Med Date: 2015-10 Impact factor: 91.245
Authors: Saakshi Khattri; Patrick M Brunner; Sandra Garcet; Robert Finney; Steven R Cohen; Margeaux Oliva; Riana Dutt; Judilyn Fuentes-Duculan; Xiuzhong Zheng; Xuan Li; Kathleen M Bonifacio; Norma Kunjravia; Israel Coats; Inna Cueto; Patricia Gilleaudeau; Mary Sullivan-Whalen; Mayte Suárez-Fariñas; James G Krueger; Emma Guttman-Yassky Journal: Exp Dermatol Date: 2016-08-09 Impact factor: 3.960
Authors: Andrew Blauvelt; Kristian Reich; Tsen-Fang Tsai; Stephen Tyring; Francisco Vanaclocha; Külli Kingo; Michael Ziv; Andreas Pinter; Ronald Vender; Sophie Hugot; Ruquan You; Marina Milutinovic; Diamant Thaçi Journal: J Am Acad Dermatol Date: 2016-09-20 Impact factor: 11.527
Authors: William J Sandborn; Christopher Gasink; Long-Long Gao; Marion A Blank; Jewel Johanns; Cynthia Guzzo; Bruce E Sands; Stephen B Hanauer; Stephan Targan; Paul Rutgeerts; Subrata Ghosh; Willem J S de Villiers; Remo Panaccione; Gordon Greenberg; Stefan Schreiber; Simon Lichtiger; Brian G Feagan Journal: N Engl J Med Date: 2012-10-18 Impact factor: 91.245
Authors: William J Sandborn; Brian G Feagan; Richard N Fedorak; Ellen Scherl; Mark R Fleisher; Seymour Katz; Jewel Johanns; Marion Blank; Paul Rutgeerts Journal: Gastroenterology Date: 2008-07-17 Impact factor: 22.682
Authors: Marc A Judson; Robert P Baughman; Ulrich Costabel; Marjolein Drent; Kevin F Gibson; Ganesh Raghu; Hidenobu Shigemitsu; Joseph B Barney; Daniel A Culver; Nabeel Y Hamzeh; Marlies S Wijsenbeek; Carlo Albera; Isham Huizar; Prasheen Agarwal; Carrie Brodmerkel; Rosemary Watt; Elliot S Barnathan Journal: Eur Respir J Date: 2014-07-17 Impact factor: 16.671
Authors: Brian G Feagan; William J Sandborn; Christopher Gasink; Douglas Jacobstein; Yinghua Lang; Joshua R Friedman; Marion A Blank; Jewel Johanns; Long-Long Gao; Ye Miao; Omoniyi J Adedokun; Bruce E Sands; Stephen B Hanauer; Severine Vermeire; Stephan Targan; Subrata Ghosh; Willem J de Villiers; Jean-Frédéric Colombel; Zsolt Tulassay; Ursula Seidler; Bruce A Salzberg; Pierre Desreumaux; Scott D Lee; Edward V Loftus; Levinus A Dieleman; Seymour Katz; Paul Rutgeerts Journal: N Engl J Med Date: 2016-11-17 Impact factor: 91.245
Authors: Christopher Ritchlin; Proton Rahman; Arthur Kavanaugh; Iain B McInnes; Lluis Puig; Shu Li; Yuhua Wang; Yaung-Kaung Shen; Mittie K Doyle; Alan M Mendelsohn; Alice B Gottlieb Journal: Ann Rheum Dis Date: 2014-01-30 Impact factor: 19.103
Authors: Rajat Garg; Manik Aggarwal; Robert Butler; Jean Paul Achkar; Bret Lashner; Jessica Philpott; Benjamin Cohen; Taha Qazi; Florian Rieder; Miguel Regueiro; Benjamin Click Journal: Dig Dis Sci Date: 2021-06-23 Impact factor: 3.487